Cellectar BiosciencesCLRB
13F holders, Q4 2025 (December 31)20holders −1
4new positions
5sold out
$3.01avg. 13F price*
At the end of Q4 2025, 20 institutions reported holding Cellectar Biosciences Inc. (CLRB) in their 13F filings, down 1 from Q3 2025. 4 opened new positions and 5 sold out. The largest holders were Bleichroeder LP ($295K), Vanguard Group Inc. ($263K) and DRW Securities, LLC ($133K).
- Company
- Cellectar Biosciences Inc.
- CUSIP
- 15117F880
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $113K |
| Exits | 5 | $316K |
All 13F filers, Q3 2025 → Q4 2025: 107,201 shares bought and 56,517 shares sold, net +50,684 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Bleichroeder LP | 0.05% | No change | 100,000 | $295K |
| Vanguard Group Inc. | 0.00% | Add +36.8% | 89,120 | $263K |
| DRW Securities, LLC | 0.01% | Add +114.2% | 45,190 | $133K |
| Geode Capital Management, LLC | 0.00% | Add +15.0% | 28,636 | $84K |
| Sequoia Financial Advisors, LLC | 0.00% | Add +135.1% | 25,350 | $75K |
| Riverview Capital Advisers, LLC | 0.02% | No change | 10,384 | $50K |
| Warberg Asset Management LLC | 0.13% | New | 13,900 | $41K |
| XTX Topco Ltd | 0.00% | New | 12,243 | $36K |
| Susquehanna International Group, LLP | 0.00% | New | 12,204 | $36K |
| BlackRock, Inc. | 0.00% | No change | 4,745 | $14K |
| UBS Group AG | 0.00% | Add +186.1% | 2,598 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +68.2% | 1,833 | $5K |
| Morgan Stanley | 0.00% | No change | 510 | $2K |
| TD Waterhouse Canada Inc. | 0.00% | New | 63 | $181 |
| Bank of America Corp. | 0.00% | Add +33.3% | 36 | $106 |
| SBI Securities Co., Ltd. | 0.00% | No change | 11 | $32 |
| Osaic Holdings, Inc. | 0.00% | Reduce -69.6% | 7 | $19 |
| US Bancorp \de | 0.00% | No change | 3 | $9 |
| Jones Financial Companies LLLP | 0.00% | No change | 3 | $9 |
| Danske Bank A/S | 0.00% | No change | 2 | $6 |
"% of holder's portfolio" is CLRB's weight in each manager's 13F, not the share of Cellectar Biosciences Inc. the manager owns.